RUO-ined: Five Peptide Vendors Learn That ‘Research Use Only’ Is Not a Legal Strategy

The Warning Letters were sent to Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC (Tex Peptides), alleging that each sold unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Each company has 15 business days to respond. The letters are straightforward unapproved-drug enforcement against online vendors and the latest move in the FDA’s systematic campaign to go after every link in the peptide supply chain. Telehealth marketers received warning letters in March and June, the compounding framework is being tightened through rulemaking, and now direct-to-consumer online vendors are receiving attention. The takeaway is that the FDA is demonstrating enforcement tools calibrated to each segment of the market.

Broader Than Weight Loss

All five letters follow a now-familiar structure: CDER reviewed each company’s website, identified products marketed with disease-treatment or body-function claims, and concluded the products are drugs under Section 201(g)(1) of the FD&C Act, making their introduction into interstate commerce a violation of Sections 301(d) and 505(a).

What makes this batch notable is not just the usual suspects (semaglutide, tirzepatide, and retatrutide appeared across multiple letters) but the rest of the lineup: tesamorelin, SS-31/elamipretide, PT-141/bremelanotide, survodutide, mazdutide, and bacteriostatic water bundled with injectable peptides. That is a wider enforcement perimeter than the weight-loss-only framing that dominated 2025.

“Research Use Only” Is Not a Regulatory Force Field

Every vendor relied on some variation of a “research use only” (RUO) disclaimer. The FDA was not persuaded. In a footnote in each letter, the agency stated that “despite statements on your product labeling,” the evidence from each website “establishes that your products are intended to be drugs for human use.” The agency looks past the label to the net impression of the website as a whole. Disease claims, dosing guidance, peptide reconstitution calculators, and bacteriostatic water sold alongside injectables all contribute. As the letter to NuScience Peptides noted, marketing bacteriostatic water alongside a “peptide calculator” that “provides the means to prepare an injectable drug for human administration” effectively answered the intended-use question. As we wrote in a prior alert, the FDA evaluates these claims under a net-impression standard, meaning even technically hedged language can render a product misbranded if the overall marketing picture is misleading. The pattern across these and prior letters suggests that RUO labeling alone is unlikely to withstand FDA scrutiny when the surrounding marketing context points toward human use.

Retatrutide: Squeezed From Both Sides

The most striking thread connecting all five letters is retatrutide, Eli Lilly’s investigational triple-agonist obesity drug. It is unapproved anywhere in the world, and an FDA submission is planned for early 2027. These Warning Letters land just weeks after Lilly filed six federal lawsuits against companies selling unauthorized retatrutide, and reported referring more than 200 entities to the FDA, US Department of Justice (DOJ), state attorneys general, and licensing boards. The convergence of federal enforcement and private brand-holder litigation around the same molecule is not a coincidence. The FDA and Lilly are squeezing the same market from different directions. Retatrutide cannot lawfully be compounded under Section 503A: it is not a component of an FDA-approved drug, does not appear on any bulk drug substances list, and lacks a United States Pharmacopeia (USP) or National Formulary (NF) monograph.

The 2026 Enforcement Arc

Vector 1: Telehealth platforms. On March 30, 30 Warning Letters were issued to telehealth companies for false or misleading claims about compounded GLP-1 products, constituting misbranding under Section 502(a). During the week of June 15, 25 more telehealth Warning Letters were issued for the same type of claims. These letters targeted telehealth marketers and rested on a misbranding theory, not the unapproved-drug theory used in the August 24 letters.

Vector 2: The regulatory and rulemaking squeeze on compounders. On April 30, a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List was published (which we discussed in detail). This is a rulemaking-driven constraint on compounders, distinct from the legal theory used in the August 24 vendor letters. If finalized, the exclusion would bar 503B outsourcing facilities from compounding these three GLP-1 products.

Vector 3: Direct-to-consumer online vendors. The August 24 letters are pure unapproved-new-drug enforcement under Sections 301(d) and 505(a), based on the vendors’ marketing of products as drugs for human use. They are aimed at a different set of market participants and rest on a separate, simpler legal theory. For online vendors outside the compounding space, these letters are a reminder that FDA’s unapproved-drug authority under Sections 301(d) and 505(a) applies independently, so no compounding nexus is required.

These are different legal theories aimed at different types of market participants, but the cumulative effect is a comprehensive enforcement posture that reaches each segment of the peptide supply chain. The throughline is unmistakable: the FDA is building an enforcement record across every segment of the peptide supply chain: telehealth platforms, compounders, and now direct-to-consumer online vendors. Moreover, industry itself is now seeking relief via the courts, with the six Lilly lawsuits noted above.

A Note on the PCAC Vote and the Compounding Landscape

Distinct from the unapproved-drug enforcement described above, the compounding regulatory landscape continues to evolve. As we wrote in our most recent alert, the Pharmacy Compounding Advisory Committee’s (PCAC)’ July 23-24 vote recommending six peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon) for the 503A Bulks List was a significant procedural milestone, but procedural is the operative word. None has been added to the bulks list. The FDA must still complete formal notice-and-comment rulemaking, a process that, as we previously discussed, has historically taken well over a year. And critically, none of the peptides flagged in these August 24 letters is among those six. It is worth underscoring that a favorable advisory vote on one set of peptides does not extend to a different set, namely, the peptides flagged in these August 24 letters, which are not among the six the PCAC recommended, and the enforcement and regulatory tracks remain distinct.

Key Takeaways for Industry

• The RUO label is not protection. Website content that includes disease claims, dosing guidance, reconstitution tools, or bacteriostatic water sold alongside injectables will be treated as evidence of intended drug use.

• Retatrutide is a particularly high-risk target. With Lilly pursuing private litigation and the FDA issuing enforcement letters, companies face two-front legal exposure.

• The enforcement perimeter is widening. Tesamorelin, elamipretide, bremelanotide, survodutide, and mazdutide in these letters signal the FDA’s focus extends well beyond weight loss.

• FDA is working every link in the chain. Online vendors, telehealth platforms, and compounders each face enforcement tailored to their business model. No segment of the peptide market is beyond the agency’s reach.

• A favorable PCAC vote does not insulate current sales. As we wrote previously, companies should resist making commercial commitments premised on regulatory outcomes that have not yet materialized.

• Monitor and prepare. The next PCAC meeting, expected before February 2027, will consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF.

Market enthusiasm continues to outpace the regulatory timeline. These five warning letters are a reminder that between a favorable advisory vote and a final rule, there is a long stretch of enforcement-eligible terrain, and the FDA has shown it intends to enforce across that entire stretch.